71 |
Avaliação dos efeitos de dois programas de exercícios terapêuticos com e sem resistência elástica em pacientes com espondilite anquilosante / Effect of two exercise therapy program with and without elastic resistance in Ankylosing Spondylitis patientsAndrea Lopes Gallinaro 17 August 2016 (has links)
Objetivo: Exercícios de mobilização são aplicados em pacientes com Espondilite Anquilosante (EA) para preservar e restaurar a mobilidade axial, no entanto, não há descrição na literatura, de um programa específico de reabilitação compreendendo apenas exercícios de mobilização com e sem a associação de exercícios com resistência elástica em pacientes com EA. Assim, foram avaliados os efeitos de dois programas de exercícios quanto a mobilidade, capacidade funcional, qualidade de vida e atividade de doença em pacientes com EA. Métodos: Cinquenta e cinco pacientes com EA, sedentários, com Índice Bath de atividade de doença da Espondilite Anquilosante (BASDAI) < 4 foram incluídos no estudo. Os pacientes com EA foram alocados ao acaso em três grupos, um grupo foi prescrito exercícios de mobilização (M), um com o programa de mobilização mais exercícios de resistência elástica (M+R) e um grupo controle sem exercícios (C). As sessões de exercícios foram realizadas em grupos, duas vezes por semana, por 16 semanas, e todas as sessões foram supervisionadas. Os grupos M e M+R realizavam 30 minutos de alongamentos e exercícios de mobilidade para coluna, membros superiores e inferiores. Depois do programa de mobilização, apenas o grupo M+R realizava mais 30 minutos de exercícios com resistência elástica. A mobilidade, qualidade de vida, atividade de doença e parâmetros de atividade funcional foram avaliados no início do programa e depois de 16 semanas por um avaliador cego. Resultados: No início do estudo, a média de idade dos pacientes (DP) era 48,2 anos ( ± 11,7); tempo de doença 18,4( ± 9,9) anos; BASDAI 2,2( ± 1,2); escore global Bath de espondilite anquilosante (BAS-g) de 4,2( ± 2,3) Índice funcional Bath (BASFI) de 3,6( ± 2,4) e Índice de mobilidade Bath (BASMI) de 4,6( ± 2,1). Comparando valores iniciais e após 16 semanas o grupo M mostrou uma melhora significante no Índice BASMI e o grupo M+R apresentou uma melhora significante no BASMI e na expansibilidade torácica. BAS-g, BASDAI e BASMI foram significantemente piores no grupo C. Não houve diferença significante entre os grupos M e M+R, mas foi encontrada diferença estatisticamente significante entre os grupos C e M+R nos índices BASDAI, ASDAS e BASFI a favor do grupo M+R. Conclusão: Os programas de exercícios terapêuticos foram seguros e efetivos. O programa de mobilização promoveu benefícios apenas nos parâmetros de mobilidade articular. Os pacientes que realizaram programa de exercícios com resistência elástica além de apresentarem melhora na mobilidade articular, apresentaram melhora da atividade de doença e função quando comparado aos controles no fim do tratamento / Objective: Mobility exercises are used in Ankylosing Spondylitis (AS) patients to preserve and restore axial mobility, but there are no data regarding a specific rehabilitation program that includes mobility alone and its association with elastic resistance exercises in AS patients with stable disease activity. So, we assessed the effects of two exercise programs in terms of mobility, functional capacity, quality of life and disease activity in AS patients. Methods: Fifty-five sedentary AS patients with a Bath Ankylosing Spondylitis Activity Index (BASDAI) <4 were included. The AS patients were randomly assigned into three groups, to receive a mobility exercise program (M), or mobility plus elastic resistance exercise program (M+R) or no exercise (C). The exercises group sessions were conducted twice per week for 16 weeks. This supervised program comprised 30 minutes of outdoor stretching and mobility exercises for the spine and limbs (M). After the mobility program, M+R group carry out more 30 minutes of elastic resistance exercises. The mobility, disease activity and functional parameters were evaluated at baseline and after 16 weeks, with the evaluator blinded to the treatment group. Results: At study entry, the patients had a mean (SD) age of 48,2 years ( ± 11,7), disease duration of 18,4( ± 9,9) years, BASDAI 2,2( ± 1,2), Bath AS Global score (BAS-g) 4,2( ± 2,3) Bath AS functional Index (BASFI) of 3,6( ± 2,4) and Bath AS Metrology Index (BASMI) of 4,6( ± 2,1). Comparing the baseline to 16 weeks, group M showed a significant improvement in BASMI and M+R group showed significant improvement in BASMI and chest expansion. BAS-g, BASDAI and BASMI was significantly worst in C group. No significant differences between M+R group and M group were perceived but there were significant differences in BASDAI, ASDAS and BASFI scores between C group and M+R group in favor of M+R group. Conclusion: Therapeutic exercises programs were effective and safe. The mobility exercises program promoted benefits only in joint mobility parameters. The exercise program with elastic resistance besides those benefits for joint mobility, also improved function and disease activity comparing to controls at the end of the program
|
72 |
Avaliação dos parâmetros clínicos da superfície ocular e da citologia de impressão conjuntival nos pacientes com olho seco associado a doença reumatológica submetidos a tratamento com terapia anti-TNF / Evaluation of ocular surface clinical parameters and conjunctival impression cytology of rheumatic disease associated dry eye patients submitted to anti-TNF therapyFany Solange Usuba 12 December 2017 (has links)
OBJETIVOS: Avaliar as alterações clínicas da superfície ocular, citologia de impressão (CI) e sintomas de olho seco (OS) dos pacientes com Espondilite Anquilosante (EA) e Artrite Reumatoide (AR). Classificar a intensidade de OS. Avaliar prospectivamente os parâmetros clínicos, laboratoriais e da superfície ocular dos pacientes com EA e AR submetidos a tratamento com drogas anti-TNF. MÉTODOS: Estudo prospectivo envolvendo inicialmente (pré-tratamento) 36 pacientes com EA e 20 pacientes com AR comparados com grupo controle de 39 voluntários saudáveis para o grupo de EA e 24 voluntários saudáveis para o grupo de AR. Do total inicial, 14 pacientes consecutivos com EA e 20 pacientes consecutivos com AR foram submetidos a terapia anti-TNF. Foram realizados os seguintes exames: teste de Schirmer I, tempo de rompimento do filme lacrimal, tingimento com corantes vitais e questionário dos sintomas de OS (Ocular Surface Disease Index-OSDI), citologia de impressão (CI) conjuntival, avaliação laboratorial inflamatória: velocidade de hemossedimentação e proteína C reativa (VHS e PCR) e atividade da doença pelas medidas de Bath Ankylosing Spondylitis Activity Index e Bath Ankylosing Spondylitis Functional Index (BASDAI e BASFI respectivamente) na EA e Disease Activity Score 28 (DAS 28) para AR. Além disso, avaliou-se a qualidade de vida pelo Health Assessment Questionnaire (HAQ) para ambas as doenças. As avaliações foram realizadas pré-tratamento e repetidas aos 3 meses (3M) e 12 meses (12M) após o início da terapia. RESULTADOS: Na avaliação pré-tratamento com drogas anti-TNF, os pacientes com EA apresentaram OS de intensidade leve a moderada (80,5% versus 43,6%, p=0,01) e maior escore de alteração da CI (55% versus 12,8%, p=0,007) associados a provas de atividade inflamatórias elevadas (p < 0,001) quando comparados com controles saudáveis. A avaliação longitudinal do tratamento com terapia anti-TNF demonstrou melhora da produção aquosa lacrimal (pré-tratamento: 13,7 ? 11,3 mm, aos 3M: 18,3 +- 11,1 mm e aos 12M: 19,3 +- 9,0 mm, p=0,04) assim como da CI conjuntival (pré-tratamento: 78,6% alterada, aos 3M: 57,1%, e aos 12M: 35,7%, p=0,03). Houve, paralelamente, melhora dos parâmetros inflamatórios e da atividade da doença (p < 0,05). No grupo de pacientes com AR, no momento pré-tratamento com drogas anti-TNF, foram observados maior frequência (75% versus 4%, p < 0,001) e intensidade leve de OS (65% versus 4%, p < 0,001) associados a sintomas moderados (escore OSDI 24,0 +- 17,6 versus 7,5 +- 14,3, p=0,001) quando comparados com controles saudáveis. Esses pacientes também apresentaram maior frequência de disfunção das glândulas de meibômio (55,0% versus 8,3%, p=0,001), maior escore de alteração da CI conjuntival (1,0 +- 0,6 versus 0.0 +- 0,2, p=0,001) e menor densidade de células caliciformes (431,3 +- 209,5 células/mm2 versus 804,8 +- 383,2 células/mm2, p < 0,001) quando comparados com o grupo controle. A análise prospectiva dos pacientes com AR tratados com drogas anti-TNF mostrou um aumento dos valores do teste de Schirmer (prétratamento: 11,8 +- 6,7 mm, aos 3M: 21,0 +- 10,4 mm, e aos 12M: 23,0 +- 9,7mm, p < 0,001), melhora da CI conjuntival (pré-tratamento: 1,0 +- 0,6, aos 3M: 0,8 +- 0,6, e aos 12M: 0,5 +- 0,5, p=0,005) e da densidade de células caliciformes (pré-tratamento: 429 +- 211,7 células/mm2, aos 3M: 908 +- 291,4 células/mm2, e aos 12M: 1265,4 +- 430,6 células/mm2, p=0,001). Os marcadores de atividade inflamatória sistêmicos (VHS e PCR) também melhoraram ao longo do tratamento (p=0,005 e p=0,006, respectivamente). CONCLUSÃO: Os pacientes com EA e AR avaliados nesse estudo apresentaram prevalência elevada de OS de intensidade leve a moderada associada à alteração da citologia conjuntival. A recuperação precoce e manutenção de longo prazo na produção aquosa da lágrima e na CI conjuntival, em especial, das células caliciformes, nos pacientes submetidos a terapia anti-TNF, pode refletir a melhora da condição inflamatória. Esse resultado histológico pode ter influência como biomarcador da inflamação na superfície ocular / OBJECTIVES: Evaluate ocular surface parameters, impression cytology (IC) and dry eye (DE) symptoms of patients with Ankylosing Spondylitis (AS) and Rheumatoid Arthritis (RA). Classify DE severity grade. Analyse prospectively clinical and laboratory, as well as ocular surface parameters of AS and RA patients, submitted to anti-TNF therapy. METHODS: This prospective study initially (baseline) enrolled 36 AS patients and 20 RA patients who were compared to a control group of 39 and 24 healthy volunteers for the AS group and RA group, respectively. From the initial group, 14 consecutive AS and 20 consecutive RA patients received anti-TNF therapy. They underwent the following exams: Schirmer I test, tear break-up time, vital dyes staining of the ocular surface, a questionnaire for dry eye symptoms- Ocular Surface Disease Index (OSDI), and conjunctival IC. Laboratory tests for inflammatory activity were assessed by erythrocyte sedimentation rate and C- reactive protein (ESR and CRP). The Bath Ankylosing Spondylitis Activity Index and Bath Ankylosing Spondylitis Functional Index (BASDAI and BASFI, respectively) in AS and Disease Activity Score 28 (DAS 28) in RA analyzed disease activity parameters. Besides, the Health Assessment Questionnaire evaluated the quality of life in both group of diseases. These measurements were taken at baseline (BL) and repeated at 3 months and 12 months (3M and 12M, respectively) after the beginning of anti-TNF therapy. RESULTS: At the baseline moment, AS patients presented mild to moderate DE (80.5% vs 43.6%, p=0.01) and a higher score of altered IC (55% vs 12.8%, p=0.007) associated with the systemic inflammatory activity (ESR and CRP, p < 0.001) when compared to healthy volunteers. The longitudinal evaluation of anti- TNF treatment showed an improvement of aqueous tear production (BL: 13.7 +- 11.3 mm, 3M: 18.3 +- 11.1 mm and 12M: 19.3 +- 9,0 mm, p=0.04). The IC also improved (BL: 78.6% altered IC, 3M: 57.1% and 12M: 35.7%, p=0.03). There was a parallel amelioration of systemic inflammatory markers and disease activity (p < 0.05). Concerning the RA group of patients, at the baseline moment, there was a higher frequency of DE (75% vs 4%, p < 0.001) as well as mild DE severity grade (65% vs 4%, p < 0,001) associated with moderate symptoms of DE (OSDI score: 24.0 +- 17.6 vs 7.5 +- 14.3, p=0.001) when compared to healthy volunteers. This group of patients also presented higher frequency of meibomian gland dysfunction (55% vs 8.3%, p=0.001), a worse score of IC (1.0 +- 0.6 vs 0.0 ? 0.2, p=0.001) and lower goblet cells count (431.3 +- 209.5 cells/mm2 vs 804.8 +- 383.2 cells/mm2, p< 0.001) when compared to the control group. The prospective analysis of RA patients treated with anti-TNF drugs demonstrated an increase of Schirmer\'s test (BL: 11.8 +- 6.7, 3M: 21.0 +- 10.4, 12M: 23.0 +- 9.7, p < 0.001) and an improvement of cytological grade (BL: 1.0 +- 0.6, 3M: 0.8 +- 0.6, 12M: 0.5 +- 0.5, p=0.005) and goblet cells density (BL: 429,0 +- 211.7 cells/mm2, 3M: 908,0 +- 291.4 cells/mm2, 12M: 1265.4 +- 430.6 cells/mm2, p=0.001). The systemic inflammatory markers (ESR and CRP) also improved throughout the treatment period (p=0.005 and p=0.006, respectively). CONCLUSION: Patients with AS and RA enrolled in this study presented a higher prevalence of mild to moderate DE associated with altered IC. The prompt and maintained aqueous tear and conjunctival cytology recovery, especially the goblet cells, in patients submitted to anti-TNF therapy seem to represent the improvement of inflammatory condition. This histological outcome may have an influence as a biomarker of ocular surface inflammation
|
73 |
Léčba pacientů specializovaným pracovištěm - centrem pro léčbu revmatologických onemocnění pro Jihočeský kraj / Treatment of Patients in a Specialized Establishment - a Centre for the Cure of Rheumatological Disorders in the South Bohemian RegionValentová, Monika January 2009 (has links)
Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis belong among serious disorders, that effect joints and connective tissue. The patients suffer from pain and stiffness. Disease modifying drugs are an important part in the management of rheumatical disorders. When disease modifying drugs are failing, than biologic treatment is applied. For biologic treatment are registred etanercept (Enbrel), adalimumab (Humira), rituximab (MabThera), abatacept (Orencia) and infliximab (Remicade). In the Czech Republic was established the National registry of rheumatic disorders. There is a need of long term observations of patients, who have biologic treatment, to evaluate safety and socioeconomic data of the biologic treatment.
|
74 |
Biomarkery zánětlivého postižení subchondrální kosti při axiální spondyloartritidě. / Biomarkers of subchondral bone damage caused by inflammation in axial spondyloarthritis.Bubová, Kristýna January 2020 (has links)
Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting primarily the spine and its adjacent structures. The disease is characterized not only by destructive joint changes but also by excessive osteoproduction, which can lead to gradual ankylosis of the spine and thus significantly reduce the mobility and quality of life. The pathogenesis of the disease is not yet fully understood, but a strong genetic background is suggested, along with dysregulation of tissue metabolism resulting from an imbalance of pro- and anti-inflammatory immune mechanisms. We are still lacking biomarker with sufficient sensitivity and specificity which could help to identify early diagnosis, to monitor subchondral damage, and to differentiate rapidly progressing patients. The aim of this work was to determine the levels of potential biomarkers of connective tissue metabolism, fat metabolism and new promising biomarkers for both disease subtypes, their relationship to disease activity and progressive structural changes. Results: We have shown increased serum/plasma levels of connective tissue metabolism biomarkers (especially matrix metalloproteinase mediated metabolites), which were able to differentiate patients with early and late forms of axSpA from healthy individuals (HC), were...
|
75 |
Efficacy When Using Biosimilar Renflexis (infliximab abda) Compared to Biologic Remicade (infliximab) Indicated for Treatment of Patients Diagnosed with Rheumatoid Arthritis and Spondyloarthritis.Silversteyn, Laura 29 March 2022 (has links)
No description available.
|
76 |
Efeito da inflamação no peptídeo natriurético atrial (NT-proBNP) em pacientes com espondilite anquilosante ativa durante terapia anti-TNF / Effect of inflammation on atrial natriuretic peptide (NT-proBNP) levels in active ankylosing spondylitis patients receiving anti-TNF therapyMoraes, Júlio César Bertacini de 21 October 2013 (has links)
Introdução: O fragmento amino-terminal do pró-peptídeo natriurético do tipo B (NT-proBNP) é um forte marcador de doença cardiovascular com evidências recentes de que a inflamação também pode influenciar seus valores. A diferenciação dessa variável de confusão é de particular interesse nas doenças reumáticas. Objetivos: Avaliar o comportamento dos valores de NT-proBNP em pacientes com espondilite anquilosante (EA) pré e pós uso de bloqueadores de TNF para determinar a possível associação entre os valores de NT-proBNP e os parâmetros inflamatórios. Métodos: Quarenta e cinco pacientes consecutivos com EA sem evidência prévia ou atual de doença cardiovascular ou disfunção miocárdica sistólica e que eram elegíveis para terapia anti-TNF foram incluídos prospectivamente. Todos os pacientes receberam bloqueadores de TNF e foram avaliados para concentrações circulantes de NT-proBNP, parâmetros clínicos e laboratoriais de atividade de doença, fatores de risco cardiovasculares tradicionais e ecodopplercardiografia convencional e tecidual no momento da inclusão e após seis meses de tratamento. Resultados: No momento da inclusão, todos os pacientes tinham EA ativa, os valores de NT-proBNP tinham uma mediana de 36 (20-72) pg/mL e 11% dos valores estavam altos mesmo na ausência de alteração miocárdica sistólica. A análise de regressão linear múltipla revelou que esse peptídeo estava independentemente correlacionado com o VHS (p < 0,001), com a idade dos pacientes (p = 0,01) e com a pressão de pulso (p = 0,01) no momento da inclusão. Após seis meses, todos os parâmetros relacionados a doença de base melhoraram e os valores de NT-proBNP se reduziram significativamente [24 (16-47) pg/mL, p = 0,037] quando comparados com os valores do momento da inclusão. As mudanças nos valores de NT-proBNP correlacionaram-se positivamente com as mudanças nos valores do VHS (r = 0,41, p = 0.006). Os fatores de risco cardiovasculares avaliados permaneceram estáveis durante o seguimento. Conclusão: As elevações nos valores de NT-proBNP devem ser interpretadas com cuidado nos pacientes com EA ativa e sem evidência de doença cardiovascular. A redução no curto prazo dos valores de NT-proBNP nesses pacientes recebendo terapia anti-TNF parece refletir uma melhora do estado inflamatório / Introduction: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular disease with recent evidence that inflammation may also influence its levels; discrimination of this confounding variable is of particular interest in rheumatic diseases. Objectives: to evaluate NT-proBNP in ankylosing spondylitis (AS) patients pre- and post-TNF blocker to determine the possible association between NT-proBNP levels and inflammatory parameters. Methods: Forty-five consecutive AS patients without previous/current cardiovascular disease or systolic myocardial dysfunction, who were eligible to anti-TNF therapy, were prospectively enrolled. All patients received TNF blockers and they were evaluated for circulating NT-proBNP levels, clinical and laboratory parameters of disease activity, traditional cardiovascular risk factors, and conventional and tissue Doppler imaging echocardiography at baseline (BL) and six months after (6M) treatment. Results: At BL, all patients had active AS, NT-proBNP levels had a median of 36 (20-72) pg/mL and 11% were high in spite of no systolic alteration. Multiple linear regression analysis revealed that this peptide, at BL, was independently correlated with ESR (p < 0.001), age (p = 0.01) and pulse pressure (p = 0.01). After 6M, all disease parameters improved and NT-proBNP levels were significantly reduced [24 (16-47) pg/mL, p = 0.037] compared to BL. Changes in NT-proBNP were positively correlated with ESR changes (r = 0.41, p = 0.006). Cardiovascular risk factors remained stable during follow-up. Conclusion: our data suggests that elevations of NT-proBNP should be interpreted with caution in active AS patients with no other evidence of cardiovascular disease. The short-term reduction of NT-proBNP levels in these patients receiving anti-TNF therapy appears to reflect an improvement in inflammatory status
|
77 |
Efeito da inflamação no peptídeo natriurético atrial (NT-proBNP) em pacientes com espondilite anquilosante ativa durante terapia anti-TNF / Effect of inflammation on atrial natriuretic peptide (NT-proBNP) levels in active ankylosing spondylitis patients receiving anti-TNF therapyJúlio César Bertacini de Moraes 21 October 2013 (has links)
Introdução: O fragmento amino-terminal do pró-peptídeo natriurético do tipo B (NT-proBNP) é um forte marcador de doença cardiovascular com evidências recentes de que a inflamação também pode influenciar seus valores. A diferenciação dessa variável de confusão é de particular interesse nas doenças reumáticas. Objetivos: Avaliar o comportamento dos valores de NT-proBNP em pacientes com espondilite anquilosante (EA) pré e pós uso de bloqueadores de TNF para determinar a possível associação entre os valores de NT-proBNP e os parâmetros inflamatórios. Métodos: Quarenta e cinco pacientes consecutivos com EA sem evidência prévia ou atual de doença cardiovascular ou disfunção miocárdica sistólica e que eram elegíveis para terapia anti-TNF foram incluídos prospectivamente. Todos os pacientes receberam bloqueadores de TNF e foram avaliados para concentrações circulantes de NT-proBNP, parâmetros clínicos e laboratoriais de atividade de doença, fatores de risco cardiovasculares tradicionais e ecodopplercardiografia convencional e tecidual no momento da inclusão e após seis meses de tratamento. Resultados: No momento da inclusão, todos os pacientes tinham EA ativa, os valores de NT-proBNP tinham uma mediana de 36 (20-72) pg/mL e 11% dos valores estavam altos mesmo na ausência de alteração miocárdica sistólica. A análise de regressão linear múltipla revelou que esse peptídeo estava independentemente correlacionado com o VHS (p < 0,001), com a idade dos pacientes (p = 0,01) e com a pressão de pulso (p = 0,01) no momento da inclusão. Após seis meses, todos os parâmetros relacionados a doença de base melhoraram e os valores de NT-proBNP se reduziram significativamente [24 (16-47) pg/mL, p = 0,037] quando comparados com os valores do momento da inclusão. As mudanças nos valores de NT-proBNP correlacionaram-se positivamente com as mudanças nos valores do VHS (r = 0,41, p = 0.006). Os fatores de risco cardiovasculares avaliados permaneceram estáveis durante o seguimento. Conclusão: As elevações nos valores de NT-proBNP devem ser interpretadas com cuidado nos pacientes com EA ativa e sem evidência de doença cardiovascular. A redução no curto prazo dos valores de NT-proBNP nesses pacientes recebendo terapia anti-TNF parece refletir uma melhora do estado inflamatório / Introduction: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a strong marker of cardiovascular disease with recent evidence that inflammation may also influence its levels; discrimination of this confounding variable is of particular interest in rheumatic diseases. Objectives: to evaluate NT-proBNP in ankylosing spondylitis (AS) patients pre- and post-TNF blocker to determine the possible association between NT-proBNP levels and inflammatory parameters. Methods: Forty-five consecutive AS patients without previous/current cardiovascular disease or systolic myocardial dysfunction, who were eligible to anti-TNF therapy, were prospectively enrolled. All patients received TNF blockers and they were evaluated for circulating NT-proBNP levels, clinical and laboratory parameters of disease activity, traditional cardiovascular risk factors, and conventional and tissue Doppler imaging echocardiography at baseline (BL) and six months after (6M) treatment. Results: At BL, all patients had active AS, NT-proBNP levels had a median of 36 (20-72) pg/mL and 11% were high in spite of no systolic alteration. Multiple linear regression analysis revealed that this peptide, at BL, was independently correlated with ESR (p < 0.001), age (p = 0.01) and pulse pressure (p = 0.01). After 6M, all disease parameters improved and NT-proBNP levels were significantly reduced [24 (16-47) pg/mL, p = 0.037] compared to BL. Changes in NT-proBNP were positively correlated with ESR changes (r = 0.41, p = 0.006). Cardiovascular risk factors remained stable during follow-up. Conclusion: our data suggests that elevations of NT-proBNP should be interpreted with caution in active AS patients with no other evidence of cardiovascular disease. The short-term reduction of NT-proBNP levels in these patients receiving anti-TNF therapy appears to reflect an improvement in inflammatory status
|
78 |
Genetics of ankylosing spondylitisKaraderi, Tugce January 2012 (has links)
Ankylosing spondylitis (AS) is a common inflammatory arthritis of the spine and other affected joints, which is highly heritable, being strongly influenced by the HLA-B27 status, as well as hundreds of mostly unknown genetic variants of smaller effect. The aim of my research was to confirm some of the previously observed genetic associations and to identify new associations, many of which are in biological pathways relevant to AS pathogenesis, most notably the IL-23/T<sub>H</sub>17 axis (IL23R) and antigen presentation (ERAP1 and ERAP2). Studies presented in this thesis include replication and refinement of several potential associations initially identified by earlier GWAS (WTCCC-TASC, 2007 and TASC, 2010). I conducted an extended study of IL23R association with AS and undertook a meta-analysis, confirming the association between AS and IL23R (non-synonymous SNP rs11209026, p=1.5 x 10-9, OR=0.61). An extensive re-sequencing and fine mapping project, including a meta-analysis, to replicate and refine the association of TNFRSF1A with AS was also undertaken; a novel variant in intron 6 was identified and a weak association with a low frequency variant, rs4149584 (p=0.01, OR=1.58), was detected. Somewhat stronger associations were seen with rs4149577 (p=0.002, OR=0.91) and rs4149578 (p=0.015, OR=1.14) in the meta-analysis. Associations at several additional loci had been identified by a more recent GWAS (WTCCC2-TASC, 2011). I used in silico techniques, including imputation using a denser panel of variants from the 1000 Genomes Project, conditional analysis and rare/low frequency variant analysis, to refine these associations. Imputation analysis (1782 cases/5167 controls) revealed novel associations with ERAP2 (rs4869313, p=7.3 x 10-8, OR=0.79) and several additional candidate loci including IL6R, UBE2L3 and 2p16.3. Ten SNPs were then directly typed in an independent sample (1804 cases/1848 controls) to replicate selected associations and to determine the imputation accuracy. I established that imputation using the 1000 Genomes Project pilot data was largely reliable, specifically for common variants (genotype concordence~97%). However, more accurate imputation of low frequency variants may require larger reference populations, like the most recent 1000 Genomes reference panels. The results of my research provide a better understanding of the complex genetics of AS, and help identify future targets for genetic and functional studies.
|
Page generated in 0.054 seconds